Optimal length of triple therapy for H pylori eradication in a population with high prevalence of infection in Chile

World Journal of Gastroenterology

Volumn 13, Issue 21, 2007, Pages 2967-2972

  Riquelme, Arnoldo ^a   Soza, Alejandro ^a   Pedreros, Cesar ^b   Bustamante, Andrea ^b   Valenzuela, Felipe ^b   Otarola, Francisco ^a   Abbott, Eduardo ^a   Arellano, Marco ^a   Medina, Brenda ^b   Pattillo, Alejandro ^a   Greig, Douglas ^a   Arrese, Marco ^a   Rollan, Antonio ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b Hospital de Urgencia Asistencia Pública Doctor Alejandro del Rio   (Chile)

Author keywords

Amoxicillin; Antibiotic treatment; Clarithromycin; Helicobacter pylori; Omeprazole; Quasi randomized controlled trial

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; OMEPRAZOLE; UREASE;

ABDOMINAL PAIN; ADULT; ANOREXIA; ARTICLE; CHILE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DYSPEPSIA; ENZYME ASSAY; FECES COLOR; FEMALE; FOLLOW UP; GASTROINTESTINAL ENDOSCOPY; HEADACHE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PATIENT COMPLIANCE; PEPTIC ULCER; PREVALENCE; RASH; SIDE EFFECT; SMOKING; STOMACH BIOPSY; TASTE DISORDER; TONGUE DISEASE; TREATMENT OUTCOME; VOMITING;

EID: 34447098830     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v13.i21.2967     Document Type: Article

References (44)

1. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002; 347: 1175-1186
2. Bazzoli F, Bianchi Porro G, Bianchi MG, Molteni M, Pazzato P, Zagari RM. Treatment of Helicobacter pylori infection. Indications and regimens: an update. Dig Liver Dis 2002; 34: 70-83
3. Forman D, Graham DY. Review article: impact of Helicobacter pylori on society-role for a strategy of 'search and eradicate'. Aliment Pharmacol Ther 2004; 19 Suppl 1: 17-21
4. Miehlke S, Bayerdorffer E, Graham DY. Treatment of Helicobacter pylori infection. Semin Gastrointest Dis 2001; 12: 167-179
5. Malfertheiner P, Megraud F, O'Morain C, Hungin AP, Jones R, Axon A, Graham DY, Tytgat G. Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002; 16: 167-180
6. Nash C, Fischbach L, Veldhuyzen van Zanten S. What are the global response rates to Helicobacter pylori eradication therapy? Can J Gastroenterol 2003; 17 Suppl B: 25B-29B
7. Altintas E, Sezgin O, Ulu O, Aydin O, Camdeviren H. Maastnicht II treatment scheme and efficacy of different proton pump inhibitors in eradicating Helicobacter pylori. World J Gastroenterol 2004; 10: 1656-1658
8. Della Monica P, Lavagna A, Masoero G, Lombardo L, Crocella L, Pera A. Effectiveness of Helicobacter pylori eradication treatments in a primary care setting in Italy. Aliment Pharmacol Ther 2002; 16: 1269-1275
9. Bazzoli F, Zagari M, Pozzato P, Varoli O, Fossi S, Ricciardiello L, Alampi G, Nicolini G, Sottili S, Simoni P, Roda A, Roda E. Evaluation of short-term low-dose triple therapy for the eradication of Helicobacter pylori by factorial design in a randomized, double-blind, controlled study. Aliment Pharmacol Ther 1998; 12: 439-445
10. Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter Pylori Study Group. Gut 1997; 41: 8-13
11. Howden CW, Hunt RH. Guidelines for the management of Helicobacter pylori infection. Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol 1998; 93: 2330-2338
12. Laine L, Suchower L, Frantz J, Connors A, Neil G. Twice-daily, 10-day triple therapy with omeprazole, amoxicillin, and clarithromycin for Helicobacter pylori eradication in duodenal ulcer disease: results of three multicenter, double-blind, United States trials. Am J Gastroenterol 1998; 93: 2106-2112
13. Lam SK, Talley NJ. Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol 1998; 13: 1-12
14. Coelho LG, Leon-Barua R, Quigley EM. Latin-American Consensus Conference on Helicobacter pylori infection. Latin-American National Gastroenterological Societies affiliated with the Inter-American Association of Gastroenterology (AIGE). Am J Gastroenterol 2000; 95: 2688-2691
15. Laine L, Estrada R, Trujillo M, Fukanaga K, Neil G. Randomized comparison of differing periods of twice-a-day triple therapy for the eradication of Helicobacter pylori. Aliment Pharmacol Ther 1996; 10: 1029-1033
16. Fennerty MB, Kovacs TO, Krause R, Haber M, Weissfeld A, Siepman N, Rose P. A comparison of 10 and 14 days of lansoprazole triple therapy for eradication of Helicobacter pylori. Arch Intern Med 1998; 158: 1651-1656
17. Louw JA, Van Rensburg CJ, Moola S, Kotze D, Marks IN. Helicobacter pylori eradication and ulcer healing with daily lansoprazole, plus 1 or 2 weeks co-therapy with amoxycillin and clarithromycin. Aliment Pharmacol Ther 1998; 12: 881-885
18. Calvet X, Garcia N, Lopez T, Gisbert JP, Gene E, Roque M. A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. Aliment Pharmacol Ther 2000; 14: 603-609
19. Rollan A. Eradication of Helicobacter pylori in developing countries. Rev Med Clin 1997; 125: 939-949
20. Buiatti E, Munoz N, Vivas J, Cano E, Peraza S, Carillo E, Castro D, Sanchez V, Andrade O, Benz M. Difficulty in eradicating Helicobacter pylori in a population at high risk for stomach cancer in Venezuela. Cancer Causes Control 1994; 5: 249-254
21. Rollan A, Ferreccio C, Harris P, Serrano C, Jara A, Venegas A. Riesgo de mortalidad por cáncer gástrico e infección por Helicobacter pylori: Resultados de un estudio poblacional (abstract). Gastroenterol Latinoam 2005; 16: 390
22. Ortega J, Calvo A, Gabrielli L, Pruyas M, Villarroel L, Soza A, Riquelme A, Abbott E, Pattillo A, Rollan A. Frecuencia de infección benigna por Helicobacter pylori en pacientes con patología gastrointestinal benigna (abstract). Gastroenterol Latinoam 2005; 16: 336
23. Gonzalez C, Garcia A, Daroch F, Kawaguchi F, Solar H, Rivera N, Vega E. In vitro antimicrobial susceptibility of Helicobacter pylori strains: isolation of strains resistant to clarithromycin. Rev Med Clin 2001; 129: 643-646
24. Flores S, Opazo H, Valderrama D, Aguilera R, Marchese A, Valderrama S. Triple therapy of short-term with azithromycin, amoxycillin and omeprazole for the eradication of Helicobacter pylori. Rev Med Chil 2000; 128: 509-512
25. Calvo A, Pruyas M, Nilsen E, Verdugo P. Populational research of gastric cancer in digestive symptomatic patients, from 1996 to 2000. Rev Med Chil 2001; 129: 749-755
26. Lundell LR, Dent J, Bennett JR, Blum AL, Armstrong D, Galmiche JP, Johnson F, Hongo M, Richter JE, Spechler SJ, Tytgat GN, Wallin L. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classffication. Gut 1999; 45: 172-180
27. Scarpignato C. Towards the ideal regimen for Helicobacter pylori eradication: the search continues. Dig Liver Dis 2004; 36: 243-247
28. Bazzoli F, Pozzato P, Rokkas T. Helicobacter pylori: the challenge in therapy. Helicobacter 2002; 7 Suppl 1: 43-49
29. Bytzer P, O'Morain C. Treatment of Helicobacter pylori. Helicobacter 2005; 10 Suppl 1: 40-46
30. Francavilla R, Lionetti E, Castellaneta SP, Magista AM, Boscarelli G, Piscitelli D, Amoruso A, Di Leo A, Miniello VL, Francavilla A, Cavallo L, Ierardi E. Improved efficacy of 10-Day sequential treatment for Helicobacter pylori eradication in children: a randomized trial. Gastroenterology 2005; 129: 1414-1419
31. Perri F, Qasim A, Mamas L, O'Morain C. Treatment of Helicobacter pylori infection. Helicobacter 2003; 8 Suppl 1: 53-60
32. Gessner BD, Bruce MG, Parkinson AJ, Gold BD, Muth PT, Dunaway E, Baggett HC. A randomized trial of triple therapy for pediatric Hellcobacter pylori infection and risk factors for treatment failure in a population with a high prevalence of infection. Clin Infect Dis 2005; 41: 1261-1268
33. De Francesco V, Zullo A, Hassan C, Della Valle N, Pietrini L, Minenna MF, Winn S, Monno R, Stoppino V, Monini S, Panella C, Ierardi E. The prolongation of triple therapy for Helicobacter pylori does not allow reaching therapeutic outcome of sequential scheme: a prospective, randomised study. Dig Liver Dis 2004; 36: 322-326
34. Matsuo K, Hamajima N, Ikehara Y, Suzuki T, Nakamura T, Matsuura A, Tajima K, Tominaga S. Smoking and polymorphisms of fucosyltransferase gene Le affect success of H. pylori eradication with lansoprazole, amoxicillin, and clarithromycin. Epidemiol Infect 2003; 130: 227-233
35. Broutet N, Tchamgoue S, Pereira E, Lamouliatte H, Salamon R, Megraud F. Risk factors for failure of Helicobacter pylori therapy-results of an individual data analysis of 2751 patients. Aliment Pharmacol Ther 2003; 17: 99-109
36. Wong WM, Xiao SD, Hu PJ, Wang WH, Gu Q, Huang JQ, Xia HH, Wu SM, Li CJ, Chen MH, Cui Y, Lai KC, Hu WH, Chan CK, Lam SK, Wong BC. Standard treatment for Helicobacter pylori infection is suboptimal in non-ulcer dyspepsia compared with duodenal ulcer in Chinese. Aliment Pharmacol Ther 2005; 21: 73-81
37. Calvet X, Ducons J, Bujanda L, Bory F, Montserrat A, Gisbert JP. Seven versus ten days of rabeprazole triple therapy for Helicobacter pylori eradication: a multicenter randomized trial. Am J Gastroenterol 2005; 100: 1696-1701
38. Huang JQ, Zheng GF, Hunt RH, Wong WM, Lam SK, Karlberg J, Wong BC. Do patients with non-ulcer dyspepsia respond differently to Helicobacter pylori eradication treatments from those with peptic ulcer disease? A systematic review. World J Gastroenterol 2005; 11: 2726-2732
39. Wheeldon TU, Hoang TT, Phung DC, Bjorkman A, Granstrom M, Sorberg M. Long-term follow-up of Helicobacter pylori eradication therapy in Vietnam: reinfection and clinical outcome. Aliment Pharmacol Ther 2005; 21: 1047-1053
40. Zendehdel N, Nasseri-Moghaddam S, Malekzadeh R, Massarrat S, Sotoudeh M, Siavoshi F. Helicobacter pylori reinfection rate 3 years after successful eradication. J Gastroenterol Hepatol 2005; 20: 401-404
41. Rollan A, Giancaspero R, Fuster F, Acevedo C, Figueroa C, Hola K, Schulz M, Duarte I. The long-term reinfection rate and the course of duodenal ulcer disease after eradication of Helicobacter pylori in a developing country. Am J Gastroenterol 2000; 95: 50-56
42. Hildebrand P, Bardhan P, Rossi L, Parvin S, Rahman A, Arefin MS, Hasan M, Ahmad MM, Glatz-Krieger K, Terracciano L, Bauerfeind P, Beglinger C, Gyr N, Khan AK. Recrudescence and reinfection with Helicobacter pylori after eradication therapy in Bangladeshi adults. Gastroenterology 2001; 121: 792-798
43. Peitz U, Hackelsberger A, Malfertheiner P. A practical approach to patients with refractory Helicobacter pylori infection, or who are re-infected after standard therapy. Drugs 1999; 57: 905-920
44. Gisbert JP. The recurrence of Helicobacter pylori infection: incidence and variables influencing it. A critical review. Am J Gastroenterol 2005; 100: 2083-2099